Barclays’s CONMED CNMD Stock Holding History

Barclays’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,500	Closed	-$602K	–	5122
2023 Q4	$602K	Buy	+5,500	New	+$569K	﹤0.01%	3768

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

Barclays's CNMD Position: Q1 2026 in Review

Barclays reduced its CONMED (CNMD) stake by 73% in Q1 2026, selling an estimated $3.56M and leaving 32,730 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2671.

Barclays first reported a position in CNMD in Q2 2013 and has held it in 50 quarters since. The position peaked at $49.6M in Q2 2023. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.

Barclays held 32,730 shares of CONMED worth $1.16M as of Q1 2026.
Barclays sold 87,475 CONMED shares in Q1 2026, an estimated $3.56M.
CONMED made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2671 holding.
Barclays first reported a position in CONMED in Q2 2013 and has held it in 50 quarters since.
Barclays's CONMED position peaked at $49.6M in Q2 2023.
236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.